Glucox Biotech
The primary goal of Glucox Biotech is to develop a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance.
Management
Mona Wilcke, PhD, CEO and one of the founders of Glucox Biotech. She has a broad experience in business issues as well as research in the metabolic and diabetes field. She has been working at several biotech companies and among the Pharmacia and Accuro Immunlogy.
Per Wikström, PhD, and one of the founders of Glucox Biotech. He has many years of research experience in the pharmaceutical industry from Immunex in Seattle, Pharmacia and Pfizer, mainly in the field of metabolic disorders and projects related to insulin resistance.
Erik Walum, PhD, professor in Neurochemistry from Stockholm University and board director of Glucox Biotech. Walum has has served as head of the Pharmacology Dept. at Pharmacia&. He is presently employed at Biovitrum.
